AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 26-A-02-096.01
We recommend that CMS issue guidance on timeframes for Part D sponsors to reject payments for OTC drugs sold under obsolete Rx-only labeling after…
The recommendation, in the publisher's words
We recommend that CMS issue guidance on timeframes for Part D sponsors to reject payments for OTC drugs sold under obsolete Rx-only labeling after an Rx-to-OTC switch. This step could have helped to prevent $587.7 million in ineligible payments to pharmacies for CYs 2021 through 2023.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- August 31, 2026
- Report
- CMS Oversight Did Not Prevent Medicare Part D Sponsors From Making $587.7 Million in Ineligible Payments to Pharmacies for Drugs Available Over the Counter but Labeled as Prescription-Only (OAS-24-02-004) · find it at HHS OIG
- Kind of report
- Audit
- Agency response
- Not Yet Due (as recorded by the publisher)
- Next update expected
- February 27, 2027 (publisher's date)
- Potential savings
- $587,680,439 (the publisher's figure; not realised savings)
- Publisher topics
- Financial Stewardship, Managed Care, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.